Scleromyxoedema: symptoms, causes, tests and treatment

DermNet, a dermatology reference, explains that lichen myxoedematosus, also called papular mucinosis, is a rare skin disorder characterised by deposits of mucin in the skin. Mucin is a gel-like substance that is normally present in small amounts. It has localised and generalised forms. The localised forms are confined to a few sites, the skin does not harden and the disease is usually stable. Scleromyxoedema is the generalised form, which can involve other organs and is sometimes fatal.

It should not be confused with other conditions that thicken the skin. DermNet notes that skin and finger stiffening and reduced mouth mobility can resemble the scleroderma of systemic sclerosis, but without telangiectasia or calcinosis. Scleromyxoedema is also separate from thyroid-related myxoedema, and thyroid function is normal in the condition, which is one reason thyroid tests are part of the work-up.

According to DermNet, scleromyxoedema is characterised by widespread skin-coloured papules (small bumps) on the face, trunk and extremities. The papules are 2 to 3 mm across, waxy and closely arranged in lines, and may become red-brown. Mucous membranes and the scalp are not involved. As the condition progresses, deep furrows may develop across the brow, and the skin and fingers can stiffen, which can limit hand movement and mouth opening.

Other organs can be affected, with potentially serious consequences. DermNet lists swallowing difficulty from oesophageal involvement, inflamed and weak muscles, reduced oxygen intake from lung involvement, arthritis, Raynaud phenomenon, kidney failure, reduced blood counts and brain and peripheral nerve damage. A 2025 case report summary describes neurological, rheumatological, cardiovascular, gastrointestinal, respiratory, renal and eye changes and a severe complication called dermato-neuro syndrome characterised by fever, seizures and coma, with a mortality rate reported to exceed 20 percent.

DermNet says no specific cause has been found, but scleromyxoedema is nearly always associated with monoclonal gammopathy, usually IgG with lambda light chains, and a small increase in bone marrow plasma cells may be found. In other cases it has been reported with bone marrow cancers such as myeloma, lymphoma and leukaemia.

The 2025 case report notes that monoclonal gammopathy of undetermined significance (MGUS) accounts for around 90 percent of the gammopathies in the diagnostic criteria. MGUS is described there as an asymptomatic premalignant condition that eventually can transform into multiple myeloma, which is why people with scleromyxoedema are followed haematologically. It also states that in a review of 17 patients, bone marrow transplantation led to sustained skin remission in only 2 percent even though the haematological disorder had been cured, which illustrates that the skin disease and the paraprotein do not always rise and fall together.

DermNet says skin biopsy is the main diagnostic test and shows characteristic features. Other tests may include serum and urine protein electrophoresis for paraproteins, thyroid function tests and autoantibodies including antinuclear factor. If a paraprotein is present, referral to a haematologist and a bone marrow biopsy may be considered, and people with widespread skin involvement may be referred to a general physician for assessment of internal organ involvement.

The 2025 case report cites diagnostic criteria that combine a generalised papular and sclerodermiform rash, mucin deposition in the upper dermis with fibroblast proliferation and collagen thickening, monoclonal gammopathy and normal thyroid function. In the UK this assessment is usually coordinated by a dermatologist with haematology input, and often by a centre experienced in rare skin disease.

DermNet describes treatment of scleromyxoedema as difficult and disappointing and lists many approaches that have been tried, including isotretinoin, corticosteroids, methotrexate, UVA1 phototherapy, PUVA, intravenous immunoglobulin, plasmapheresis, electron beam radiation and dermabrasion, with chemotherapy-type agents reserved for severe and rapidly progressive disease and thalidomide an emerging option.

The 2025 case report summarises that, since the disease is rare and randomised trials are not feasible, the best available evidence, from systematic reviews and two prospective uncontrolled trials, favours high-dose intravenous immunoglobulin (IVIG) every four to six weeks. It lists thalidomide with corticosteroids as a second-line option and bortezomib and autologous bone marrow transplantation as third-line options, notes the high risk of haematological malignancy with melphalan, and says patients usually continue IVIG indefinitely because most experience recurrence if treatment is interrupted, with spontaneous remission reported in only one case report.

Decisions about IVIG, which is a blood-product therapy with its own supply and funding arrangements, are made by specialist teams. Anyone starting long-term treatment should expect monitoring of blood counts, kidney function and the paraprotein.

Because it is a chronic disease, living with it involves regular specialist follow-up. Skin stiffness can limit hand function and mouth opening, and so occupational therapy, physiotherapy and dental care are practical parts of management. Sun protection and general skin care are sensible. Swallowing difficulty, breathlessness, muscle weakness, new numbness, confusion or seizures need prompt medical attention because they may point to organ involvement.

Patient organisations for rare skin conditions and for paraprotein-related conditions can offer peer support. Ask your dermatology team to point you to those they recommend.

Call 999 or go to A&E for seizures, sudden confusion, loss of consciousness, severe breathlessness or inability to swallow. Contact your specialist team or NHS 111 promptly for fever with new neurological symptoms, which the 2025 report associates with the serious dermato-neuro syndrome, for new swelling of the legs or reduced urine output, or for a rapid worsening of skin tightness.

On the NHS, diagnosis is by a dermatologist after GP referral, with haematology and other specialties involved. Treatment with IVIG is usually delivered through hospital day units under specialist commissioning arrangements that vary between regions. Private dermatology can provide a biopsy and a second opinion, but long-term infusion therapy is normally hospital-based, so it is worth asking how ongoing treatment and monitoring would be arranged before starting.